Scalp Cooling to Prevent Hair Loss in Patients Undergoing Stem Cell Transplantation for Multiple Myeloma

Inclusion Criteria:

Age ≥18 years
ECOG performance status ≤2
Confirmed multiple myeloma diagnosis
Hair covering ≥75% of scalp on physical exam at screening visit
Planning to undergo SOC high-dose chemotherapy with melphalan (dose to be used = 140 - 200 mg/m2 (with rounding per CSMC guidelines)) followed by an autologous peripheral blood stem cell transplant.
Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria:

Prior or current use of any scalp cooling treatment
Hair covering < 75% of the scalp on physical exam at screening visit.
Medical History and Concurrent Diseases: Reynaud's disease, Cold sensitivity, Cold agglutinin disease, Cryoglobulinemia, Cryofibrinogenemia
Current spinal or neck injury that may interfere with the subject's participation for the full duration of the study, in the opinion of the treating investigator
Skin conditions such as psoriasis, eczema, malignancy, or other condition on the scalp that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
Current use of oxaliplatin
Current use of any other investigational agents
Contraindication to melphalan